Financial Ratios Veeva Systems Inc.
Equities
VEEV
US9224751084
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
246.19 USD | +0.08% | +8.71% | +27.88% |
12-06 | Veeva Systems Insider Sold Shares Worth $390,128, According to a Recent SEC Filing | MT |
12-06 | KeyBanc Raises Veeva Systems Price Target to $285 From $240, Maintains Overweight Rating | MT |
Fiscal Period: January | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.16 | 8.88 | 9.21 | 6.66 | 5.01 | |||||
Return on Total Capital | 12.15 | 11.66 | 11.93 | 8.51 | 6.33 | |||||
Return On Equity % | 20.74 | 19.33 | 16.51 | 14.72 | 12.58 | |||||
Return on Common Equity | 20.74 | 19.33 | 16.51 | 14.72 | 12.58 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 72.52 | 72.09 | 72.79 | 71.72 | 71.35 | |||||
SG&A Margin | 27.47 | 26.22 | 24.83 | 26.28 | 26.57 | |||||
EBITDA Margin % | 27.84 | 27.8 | 28.8 | 22.65 | 19.54 | |||||
EBITA Margin % | 26.96 | 27.15 | 28.34 | 22.18 | 18.97 | |||||
EBIT Margin % | 26.04 | 25.79 | 27.31 | 21.3 | 18.16 | |||||
Income From Continuing Operations Margin % | 27.27 | 25.94 | 23.09 | 22.63 | 22.24 | |||||
Net Income Margin % | 27.27 | 25.94 | 23.09 | 22.63 | 22.24 | |||||
Net Avail. For Common Margin % | 27.27 | 25.94 | 23.09 | 22.63 | 22.24 | |||||
Normalized Net Income Margin | 17.66 | 16.94 | 17.54 | 14.68 | 14.89 | |||||
Levered Free Cash Flow Margin | 33.57 | 28.86 | 34.12 | 32.79 | 31.81 | |||||
Unlevered Free Cash Flow Margin | 33.57 | 28.86 | 34.12 | 32.79 | 31.81 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.56 | 0.55 | 0.54 | 0.5 | 0.44 | |||||
Fixed Assets Turnover | 13.9 | 13.66 | 17.24 | 20.59 | 22.59 | |||||
Receivables Turnover (Average Receivables) | 2.97 | 2.83 | 2.83 | 2.91 | 2.82 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.78 | 3.23 | 3.7 | 3.94 | 4.24 | |||||
Quick Ratio | 2.74 | 3.18 | 3.65 | 3.86 | 4.17 | |||||
Operating Cash Flow to Current Liabilities | 0.79 | 0.77 | 0.91 | 0.78 | 0.77 | |||||
Days Sales Outstanding (Average Receivables) | 123 | 129.17 | 128.78 | 125.3 | 129.23 | |||||
Average Days Payable Outstanding | 17.16 | 19.1 | 15.8 | 18.57 | 19.72 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 3.29 | 2.78 | 1.87 | 1.64 | 1.2 | |||||
Total Debt / Total Capital | 3.19 | 2.71 | 1.84 | 1.61 | 1.19 | |||||
LT Debt/Equity | 2.69 | 2.27 | 1.5 | 1.34 | 1 | |||||
Long-Term Debt / Total Capital | 2.6 | 2.21 | 1.47 | 1.31 | 0.99 | |||||
Total Liabilities / Total Assets | 26.68 | 25.6 | 23.71 | 22.65 | 21.42 | |||||
Total Debt / EBITDA | 0.17 | 0.15 | 0.1 | 0.12 | 0.12 | |||||
Net Debt / EBITDA | -3.27 | -3.81 | -4.24 | -6.03 | -8.31 | |||||
Total Debt / (EBITDA - Capex) | 0.18 | 0.15 | 0.1 | 0.12 | 0.12 | |||||
Net Debt / (EBITDA - Capex) | -3.3 | -3.89 | -4.36 | -6.2 | -8.79 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 28.05 | 32.7 | 26.33 | 16.44 | 9.68 | |||||
Gross Profit, 1 Yr. Growth % | 29.79 | 31.9 | 27.55 | 14.74 | 9.1 | |||||
EBITDA, 1 Yr. Growth % | 29.73 | 33.05 | 30.86 | -8.39 | -5.38 | |||||
EBITA, 1 Yr. Growth % | 29.47 | 34.29 | 31.85 | -8.85 | -6.22 | |||||
EBIT, 1 Yr. Growth % | 29.01 | 31.99 | 33.8 | -9.18 | -6.48 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 31.02 | 26.2 | 12.47 | 14.11 | 7.79 | |||||
Net Income, 1 Yr. Growth % | 31.02 | 26.2 | 12.47 | 14.11 | 7.79 | |||||
Normalized Net Income, 1 Yr. Growth % | 32.12 | 27.8 | 30.83 | -2.58 | 11.28 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 29.25 | 24.21 | 11.44 | 14.07 | 7.33 | |||||
Accounts Receivable, 1 Yr. Growth % | 31.38 | 44.75 | 13.54 | 13.08 | 13.16 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 89 | 6.43 | -5.82 | 0.98 | -0.97 | |||||
Total Assets, 1 Yr. Growth % | 37.37 | 34.08 | 25.29 | 25.88 | 23.03 | |||||
Tangible Book Value, 1 Yr. Growth % | -2.23 | 57.05 | 38.13 | 34.77 | 29.68 | |||||
Common Equity, 1 Yr. Growth % | 34.57 | 36.07 | 28.47 | 27.63 | 24.99 | |||||
Cash From Operations, 1 Yr. Growth % | 40.71 | 26.04 | 38.68 | 2.09 | 16.77 | |||||
Capital Expenditures, 1 Yr. Growth % | -63.12 | 100.95 | 63.7 | -4.94 | 93.87 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 54.19 | 14.32 | 49.37 | 11.89 | 6.41 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 54.19 | 14.32 | 49.37 | 11.89 | 6.41 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 26.44 | 30.35 | 29.47 | 21.28 | 13.01 | |||||
Gross Profit, 2 Yr. CAGR % | 29.27 | 30.84 | 29.71 | 20.97 | 11.89 | |||||
EBITDA, 2 Yr. CAGR % | 33.6 | 31.1 | 31.95 | 9.49 | -6.9 | |||||
EBITA, 2 Yr. CAGR % | 34.01 | 31.55 | 33.07 | 9.63 | -7.55 | |||||
EBIT, 2 Yr. CAGR % | 34.93 | 30.2 | 32.9 | 10.24 | -7.84 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 41.13 | 28.58 | 19.14 | 13.29 | 10.91 | |||||
Net Income, 2 Yr. CAGR % | 41.13 | 28.58 | 19.14 | 13.29 | 10.91 | |||||
Normalized Net Income, 2 Yr. CAGR % | 36.48 | 29.67 | 29.31 | 12.9 | 4.12 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 39.24 | 26.71 | 17.65 | 12.75 | 10.65 | |||||
Accounts Receivable, 2 Yr. CAGR % |